Format

Send to

Choose Destination
Rheum Dis Clin North Am. 2002 May;28(2):343-51.

The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia.

Author information

1
Department of Rehabilitation Medicine, Faculty of Health Sciences, Linköping University, Pain Clinic, University Hospital, Linköping S-581 85, Sweden. karl-g@telia.com

Abstract

There is strong evidence that intravenous administration of ketamine following a standardized protocol could be used as a diagnostic test for a central sensitization in the central nervous system in patients with FM. The combination of a weak opioid and an NMDA-receptor antagonist with few side effects is presently a promise for treatment of pain in a subgroup of patients with FM. The response to intravenously administered ketamine may help select patients for this treatment modality.

PMID:
12122922
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center